CA2243533A1 - Therapie par promedicament a enzyme dirige par ligand - Google Patents

Therapie par promedicament a enzyme dirige par ligand Download PDF

Info

Publication number
CA2243533A1
CA2243533A1 CA 2243533 CA2243533A CA2243533A1 CA 2243533 A1 CA2243533 A1 CA 2243533A1 CA 2243533 CA2243533 CA 2243533 CA 2243533 A CA2243533 A CA 2243533A CA 2243533 A1 CA2243533 A1 CA 2243533A1
Authority
CA
Canada
Prior art keywords
enzyme
ligand
protein
cpg2
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2243533
Other languages
English (en)
Inventor
Caroline Joy Springer
Richard Marais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9601640.7A external-priority patent/GB9601640D0/en
Application filed by Individual filed Critical Individual
Publication of CA2243533A1 publication Critical patent/CA2243533A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA 2243533 1996-01-26 1997-01-24 Therapie par promedicament a enzyme dirige par ligand Abandoned CA2243533A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9601640.7A GB9601640D0 (en) 1996-01-26 1996-01-26 Ligand directed enzyme prodrug therapy
GB9601640.7 1996-01-26
PCT/GB1997/000221 WO1997026918A2 (fr) 1996-01-26 1997-01-24 Therapie par promedicament a enzyme dirige par ligand

Publications (1)

Publication Number Publication Date
CA2243533A1 true CA2243533A1 (fr) 1997-07-31

Family

ID=29422162

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2243533 Abandoned CA2243533A1 (fr) 1996-01-26 1997-01-24 Therapie par promedicament a enzyme dirige par ligand

Country Status (1)

Country Link
CA (1) CA2243533A1 (fr)

Similar Documents

Publication Publication Date Title
EP2178559B1 (fr) Exotoxines recombinantes de vibrio cholerae
US6296843B1 (en) Mutagenized IL 13-based chimeric molecules
US11976101B2 (en) Multi-level specific targeting of cancer cells
JP3747290B2 (ja) 遺伝子指向性プロドラッグ療法における酵素の表面発現
US7807778B2 (en) Cysteine-containing peptide tag for site-specific conjugation of proteins
KR20030048041A (ko) 표적-특이적 프로드럭으로서 사용하기 위한항체-사이토카인-사이토카인 억제제로 이루어진 융합단백질(셀렉토카인)
EP1194451A1 (fr) Peptides de fusion comprenant un domaine ligand peptide et un domaine de multimerisation
KR20110117651A (ko) 알부민 결합 펩티드-매개 질병 표적화
EA010055B1 (ru) ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
US11998612B2 (en) Method for conjugating antibody and physiologically active substance
AU709238B2 (en) Ligand directed enzyme prodrug therapy
ES2289754T3 (es) Sistema de alta eficacia para la liberacion de compuestos especificos de tejido que utiliza una proteina de fusion estreptavidina-proteina a.
IE83238B1 (en) Fusion proteins with monoclonal antibody, linker and beta glucuronidase for prodrug activation; preparation and use thereof
US20230303709A1 (en) Antibody Derivatives with Conditionally Enabled Effector Function
IE920630A1 (en) Fusion proteins for prodrug activation, the preparation and¹use thereof
KR19990037999A (ko) 인간 상피세포 성장인자와 인간 안지오게닌의 융합독소 단백질 및 그의 제조방법
US20020142355A1 (en) Methods for the in vivo biotin labeling of polypeptides
Zhang et al. Fusion protein of interleukin 4 and diphtherial toxin with high cytotoxicity to cancer cells

Legal Events

Date Code Title Description
FZDE Dead